Highest-materiality recent filing
HOOKIPA shareholders approve asset sale to Gilead and company dissolution
Asset sale to Gilead Sciences approved: 5,063,462 for, 239,595 against, 1,502 abstain.
HOOKIPA plans voluntary delisting and deregistration ahead of asset sale to Gilead and dissolution
Intends to voluntarily delist from Nasdaq; Form 25 expected July 29, delisting effective ~August 8, 2025.
HOOKIPA to sell HB-400/HB-500 assets to Gilead for up to $10M; board approves dissolution
Gilead to acquire HB-400 and HB-500 assets for up to $10M in cash; $3M at closing, up to $7M in transfer completion payments.
Record date for 2022 annual meeting was 78 days before the meeting (April 13 vs. June 30, 2022), violating DGCL 60-day limit.
Gilead, owning 19.4% of HOOKIPA shares, signals intent to vote for the deal and join the $30M+ fundraise.
HOOKIPA announces non-binding discussions to acquire Poolbeg Pharma in all-share deal
Poolbeg shareholders to receive 0.03 HOOKIPA shares per share; expected ~55% ownership of combined entity before planned $30M fundraise.
HOOKIPA cuts workforce ~80%, pauses eseba-vec HPV16+ trial, focuses on HB-700
Workforce reduction of ~80%; implementation begins Q4 2024, substantially complete by H1 2025.
Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)
Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.
Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024
Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.
Dr. Malte Peters appointed CEO & President effective July 22, 2024; salary $630k, RSU award $700k.
HOOKIPA reports 53% ORR in CPS≥20 subgroup from Phase2 HB-200 + pembro trial at ASCO
Among 35 evaluable first-line HPV16+ HNSCC patients, ORR 37%, CR 11%, DCR 69% per RECIST 1.1.
HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024
Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.
HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination
Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.
Pivotal Phase 2/3 trial for HB-200 + pembrolizumab in first-line HPV16+ recurrent/metastatic OPSCC; FDA alignment achieved.
HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%
Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.
the Company’s board of directors (the “Board”) appointed Julie O’Neill to serve as non-executive chair of the Board, effective as of the Effective Time.
On August 27, 2024, Jan van de Winkel, Ph.D., notified HOOKIPA Pharma Inc. (the “Company”) of his resignation as a director of the Company, effective as of August 30, 2024 at 12:00 p.m. Eastern Time
On August 27, 2024, Timothy Reilly, Ph.D., notified the Company of his resignation as a director of the Company, effective as of the Effective Time.
the Company’s board of directors (the “Board”) appointed Malte Peters, M.D., as the Company’s Chief Executive Officer and President, effective July 22, 2024.
On July 22, 2024, Reinhard Kandera separated as the Chief Financial Officer of the Company.
Mr. Kandera also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Financial Officer
On July 22, 2024, Joern Aldag separated as the Chief Executive Officer of HOOKIPA Pharma Inc. (the “Company”).
Mr. Aldag also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Executive Officer
Max materiality 0.95 · Median 0.70 · Most common event other_material